published meta-analysis   sensitivity analysis   studies

chloroquine and derivatives in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsHYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] 0.80[0.52; 1.24]HYDRA (Hernandez-Cardenas), 202110%214NAnot evaluable deathsdetailed resultsHYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] 0.80[0.52; 1.24]HYDRA (Hernandez-Cardenas), 202110%214NAnot evaluable deaths (time to event analysis only)detailed resultsHYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] 0.80[0.52; 1.24]HYDRA (Hernandez-Cardenas), 202110%214NAnot evaluable clinical improvement (time to event analysis only)detailed resultsHYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48] 1.05[0.74; 1.48]HYDRA (Hernandez-Cardenas), 202110%214NAnot evaluable hospital dischargedetailed resultsHYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42] 1.01[0.72; 1.42]HYDRA (Hernandez-Cardenas), 202110%214NAnot evaluable off oxygenationdetailed resultsHYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51] 0.98[0.64; 1.51]HYDRA (Hernandez-Cardenas), 202110%214NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-03-29 13:19 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 508,656,657,832 - roots T: 290